The Drug Enforcement Administration (DEA) has yet again increased its quota for the legal production of illegal controlled substances like psilocybin, MDMA and DMT for research purposes in 2022.
Articles
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America's First Integrative Mental Health Clinic Network
Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating "distress" among frontline healthcare practitioners.
Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing
UK-based Albert Labs receives conditional approval from the Canadian Securities Exchange (CSE) to commence trading under the symbol "ABRT". Trading expected to commence in early 2022.
Red Light Holland Reports Second Quarter 2021 Results
Red Light Holland reports its results for Q2 fiscal 2021. - Quarterly revenues up to CAD$485,738 - A 64% increase in gross profit - 56% increase in the number of retail outlets selling TRIP products
Novamind Reports Fiscal Q1 Financial Results and Operating Highlights
Novamind reports revenues of CAD$1.86 million for Q1 fiscal 2022, a 113% year-over-year increase. The company has total working capital of CAD$6.8 million
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
Florida Lawmaker Files Bill To Decriminalize All Currently Illicit Biomedicines
A Florida lawmaker introduced a bill last week to decriminalize all currently illicit drugs, provide avenues for relief for those with existing drug-related convictions and promote harm reduction services.
Montana Issues Proposed Rules for Future Cannabis Marketplace
Regulators in Montana last week issued a slate of proposed rules for the state’s coming recreational marijuana marketplace, and cannabis advocates are excited to get started.
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.
Novamind Unveils New Logo and Invests in Unified Brand
Novamind announces unified branding of all subsidiaries and brands, and includes a new corporate logo.
COMPASS Pathways granted fifth US patent for crystalline psilocybin
The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.
St. Louis Lawmakers Unanimously Approve Bill To Decriminalize Marijuana Possession And Cultivation
St. Louis lawmakers on Tuesday unanimously approved a bill to decriminalize marijuana possession and cultivation for adults.
Cybin Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities
The program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States.